View Older Stories View More Recent Stories

May 10, 2021 08:30AM Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit
Mar 29, 2021 08:05AM Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)
Mar 17, 2021 08:00AM Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 3, 2021 08:05AM Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 16, 2021 07:30AM Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology
Jan 14, 2021 08:00AM Xenetic Biosciences, Inc. to Present at NobleCon17
Jan 5, 2021 08:05AM Xenetic Biosciences, Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
Dec 14, 2020 11:15AM Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Dec 10, 2020 06:26AM Xenetic Biosciences (XBIO) Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Dec 10, 2020 12:50AM Xenetic Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Dec 9, 2020 08:38AM Xenetic Biosciences (XBIO) Reports Positive Data from PJSC Pharmsynthez's Pivotal Phase 3 Clinical Trial Utilizing PolyXen
Dec 9, 2020 08:35AM Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology
Nov 13, 2020 08:00AM Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Nov 5, 2020 08:05AM Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 6th Annual Israel Conference
Sep 9, 2020 08:35AM Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Aug 13, 2020 07:05AM Xenetic Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Jul 30, 2020 08:05AM Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Two Key Appointments
Jul 1, 2020 08:09AM Xenetic Biosciences (XBIO) Provides Development Update for Its Personalized CAR T Platform Technology, XCART
Jul 1, 2020 08:05AM Xenetic Biosciences, Inc. Provides Development Update for Its Personalized CAR T Platform Technology, XCART(TM)
Jun 16, 2020 08:05AM Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia and Belarus to Advance Development of XCART(TM) Platform
Jun 8, 2020 08:35AM Xenetic Biosciences, Inc. to Present at the Virtual Investor Fireside Chat Series
May 19, 2020 07:36AM Xenetic Biosciences (XBIO) Announces Research and Development Collaboration with Scripps Research to Advance XCART Platform
May 19, 2020 07:35AM Xenetic Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART(TM) Platform
May 14, 2020 04:05PM Xenetic Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update
Apr 15, 2020 08:35AM Xenetic Biosciences, Inc. to Present at the April 2020 Virtual Investor Summit
Apr 9, 2020 10:10AM JTC Team and LaVoieHealthScience to Host Virtual Investor Summit on April 22 and 23, 2020
Mar 27, 2020 09:00AM Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update
Feb 27, 2020 08:00AM Xenetic Biosciences' Webcast Replay from Noble Capital Markets' 16th Annual Investor Conference Presentation Now Available
Feb 26, 2020 08:00AM Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board
Feb 13, 2020 08:00AM Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board
Feb 11, 2020 08:05AM Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference
Jan 14, 2020 08:42AM Xenetic Biosciences (XBIO) Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen Platform Technology
Jan 14, 2020 08:35AM Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology
Nov 15, 2019 08:30AM Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Oct 29, 2019 07:05AM Xenetic Biosciences, Inc. to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
Oct 16, 2019 08:05AM Xenetic Biosciences, Inc. to Present at BIO Investor Forum
Oct 8, 2019 08:34AM Xenetic Biosciences (XBIO) Provides Business Outlook
Oct 8, 2019 08:30AM Xenetic Biosciences, Inc. Provides Business Outlook
Aug 15, 2019 07:35AM Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 22, 2019 08:00AM Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform
Jun 24, 2019 09:13AM Xenetic Biosciences (XBIO) Announces 1-for-12 Reverse Stock Split of Common Stock
Jun 24, 2019 09:08AM Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
May 13, 2019 08:05AM Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 13, 2019 08:05AM Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 2, 2019 07:05AM Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.
Apr 1, 2019 07:30AM Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update
Mar 5, 2019 09:32AM Xenetic Biosciences (XBIO) Prices $3.1M Registered Direct Offering
Mar 5, 2019 09:27AM Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering
Mar 4, 2019 08:12AM Xenetic Biosciences (XBIO) Reports Acquisition of XCART Technology Platform
Mar 4, 2019 08:00AM Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform
View More Recent Stories View Older Stories